A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.
about
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Current and future pharmacological therapies for NAFLD/NASH.Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative.Macrophage p38 kinase inhibition for liver regeneration.Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?Recent advances in understanding and managing non-alcoholic fatty liver disease.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.Obesity and nonalcoholic fatty liver disease: current perspectivesThe Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune CholangitisRecommendations for the management of non-alcoholic fatty liver disease (NAFLD)Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver DiseaseCarcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancerImatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liverAdapted Immune Responses of Myeloid-Derived Cells in Fatty Liver DiseaseEmerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
P2860
Q41921861-A648FD99-DD6C-4B54-8ADA-AF2759B9AE9CQ47778507-8D1BF814-8BDD-4E3C-8868-E67B44F4EEF5Q48245745-B21D1245-7713-40B1-A5E0-210732207C1FQ48565990-87201D74-8FCD-44AF-8812-F7DFCF0D00CCQ49790075-8DD93DDC-B9E6-4C31-8077-CEA2C3547647Q51759923-0B8C4019-AFC5-48D0-8FF4-4CE445185C94Q52644936-53ED07AD-CBDD-4040-8B15-56E4C50CFC65Q54232638-791A53B3-A720-48B0-88BD-76C22AA37C21Q55359842-600121C0-A0F8-4E1D-B8D8-091B7EC6FC81Q55436995-C1193EFA-0ECF-448F-8A2E-96C1C895521BQ55656994-9DE1A84E-0E5C-4231-B40E-2362BDFDB8DAQ57069715-6CD1B7B8-02F2-4FB4-BE0F-45014523D340Q57111773-53542AF0-E386-4E67-8ADF-92D9E4695F2FQ57494353-2C015FB9-9891-47B3-ABE0-C1EDA0C753A0Q57646673-7415D23D-073A-4686-BC4E-C1DEC728FE5AQ57807125-9F0D422B-9C19-460F-B3C7-DBB4ADF896B7Q58548865-72FA54C1-1B66-4888-98A7-18818F6BB7CCQ58596151-79B4F48A-7DAF-4DB7-9A32-E310FF12DB5EQ58716313-ED2929BB-55DF-42F6-8117-D01E446D919F
P2860
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A Randomized, Placebo-Controll ...... Steatohepatitis with Fibrosis.
@en
type
label
A Randomized, Placebo-Controll ...... Steatohepatitis with Fibrosis.
@en
prefLabel
A Randomized, Placebo-Controll ...... Steatohepatitis with Fibrosis.
@en
P2093
P2860
P50
P356
P1433
P1476
A randomized, placebo-controll ...... steatohepatitis with fibrosis
@en
P2093
Antonio Craxi
Arun Sanyal
Brian L Wiens
Eric Lefebvre
Geoffrey Farrell
Jeffrey Vest
Juan Caballeria
Kris V Kowdley
Laurent Fischer
Liza Melchor-Khan
P2860
P304
P356
10.1002/HEP.29477
P407
P577
2018-01-29T00:00:00Z